462 related articles for article (PubMed ID: 7682159)
1. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
[TBL] [Abstract][Full Text] [Related]
2. Formation of the terminal complement complex on agarose beads: further evidence that vitronectin (complement S-protein) inhibits C9 polymerization.
Johnson E; Berge V; Høgåsen K
Scand J Immunol; 1994 Mar; 39(3):281-5. PubMed ID: 7510414
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibition by human vitronectin involves non-heparin binding domains.
Sheehan M; Morris CA; Pussell BA; Charlesworth JA
Clin Exp Immunol; 1995 Jul; 101(1):136-41. PubMed ID: 7542572
[TBL] [Abstract][Full Text] [Related]
4. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities.
Tschopp J; Masson D; Schäfer S; Peitsch M; Preissner KT
Biochemistry; 1988 May; 27(11):4103-9. PubMed ID: 2458130
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
6. S-protein/vitronectin interaction with the C5b and the C8 of the complement membrane attack complex.
Su HR
Int Arch Allergy Immunol; 1996 Aug; 110(4):314-7. PubMed ID: 8768797
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
Rosenfeld SI; Packman CH; Leddy JP
J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
[TBL] [Abstract][Full Text] [Related]
8. The killer molecule of complement.
Müller-Eberhard HJ
J Invest Dermatol; 1985 Jul; 85(1 Suppl):47s-52s. PubMed ID: 3891882
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.
Podack ER; Preissner KT; Müller-Eberhard HJ
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():89-96. PubMed ID: 6587746
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane channel-formation by five complement proteins.
Müller-Eberhard HJ
Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
[TBL] [Abstract][Full Text] [Related]
11. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
12. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization.
McDonald JF; Nelsestuen GL
Biochemistry; 1997 Jun; 36(24):7464-73. PubMed ID: 9200695
[TBL] [Abstract][Full Text] [Related]
14. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
15. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
Bhakdi S; Tranum-Jensen J
J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
[TBL] [Abstract][Full Text] [Related]
16. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
17. The complement SC5b-9 complex mediates cell adhesion through a vitronectin receptor.
Biesecker G
J Immunol; 1990 Jul; 145(1):209-14. PubMed ID: 1694202
[TBL] [Abstract][Full Text] [Related]
18. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
19. Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins.
Podack ER; Biesecker G; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1979 Feb; 76(2):897-901. PubMed ID: 284414
[TBL] [Abstract][Full Text] [Related]
20. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.
Bhakdi S; Käflein R; Halstensen TS; Hugo F; Preissner KT; Mollnes TE
Clin Exp Immunol; 1988 Dec; 74(3):459-64. PubMed ID: 2466593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]